louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01791322: NovellusDx Tissue Collection Protocol
Official title: An Observational Study to Assess the Oncogenic Status of Colorectal Cancer Patients That Have Undergone Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Patients That Have Been Diagnosed With Colorectal Cancer
Patients Eligible for Tumor Biopsy
Lead sponsor: Fore Biotherapeutics
Sponsor class: INDUSTRY
First posted: 2013-02-13
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients that have been diagnosed with cancer and are eligible for tumor biopsy will be enrolled.

Brief summary: NovellusDx is developing a diagnostic platform for the personalized cancer therapy based on patient derived tumor tissue. The assay is able to sense activating mutations by monitoring their effect on a chip-based device.


Eligibility criteria: Inclusion Criteria:

* Patients that have been diagnosed positive for colon cancer.
* available treatment follow up during cancer treatment

Exclusion Criteria:

* None

Primary outcomes:
measure: Correct identification of tumor mutant genes
timeFrame: up to 12 month
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Pathology Lab Hadassah Medical Center
Study officials:
affiliation: Pathology lab Hadassah MC
name: Yakov Felig, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03131622: Impact of Ibis on Patients With Advanced COPD
Official title: Impact of Ibis, a Digital Health Solution for Patient Activation and Early Intervention, on Acute Care Utilization by Patients With Advanced COPD
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: COPD
Lead sponsor: Senscio Systems
Sponsor class: INDUSTRY
Collaborators: name: Central Maine Medical Family
First posted: 2017-04-27
Enrollment: 240
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients with COPD.


Eligibility criteria: Inclusion Criteria:

* Gold Stage II with a CAT Score above 19
* Gold Stage III/IV with a CAT Score above 14

Exclusion Criteria:

* Cognitive or physical impediments that inhibits patients from interacting with our digital therapeutics platform.

Primary outcomes:
measure: Reduction in Acute Care Utilization
timeFrame: 6 months and then again at 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03363022: To Assess the Role of Fecal Microbiota Transplant in Acute Liver Failure
Official title: To Assess the Role of Fecal Microbiota Transplant in Acute Liver Failure- A Double Blind Controlled Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Acute Liver Failure
Lead sponsor: Institute of Liver and Biliary Sciences, India
Sponsor class: OTHER
First posted: 2017-12-05
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: All patients of Acute liver failure not meeting the KCH (King's College Hospital) criteria/or meeting KCH criteria not having option of liver transplant will be recruited for the trial. The first group will receive Standard medical care with Fecal Microbiota transplant on Day 1 for 3 consecutive days. FMT (Fecal Microbiota Transplant) will be delivered rectally which will be placed bedside. Suitable donor will be screened and the stool samples will be used as per criteria. Stool samples will be taken at the time at Day 0, 1(Post FMT), Day 4, 6, 14,21. Sepsis screen will be sent. Inflammatory markers will be sent on Day 0,1, 4,6, 14,21. The second group will receive standard medical therapy/and an placebo. Stool samples will be sent on Day 0,1, 4, 6 , 14,21. Inflammatory markers will be sent on the time on day 0,1 4,6 , 14,21.


Eligibility criteria: Inclusion Criteria:

Acute liver failure -Not meeting KCH Criteria/Meeting KCH Criteria but not having Liver transplant option

Exclusion Criteria:

1. Culture Positive Sepsis
2. History of taking lactulose, rifaximin, neomycin, metronidazole, L-Ornithine L-Aspartate
3. Receiving psychoactive drugs, promotility and hypomotility drugs
4. Pregnant females

Primary outcomes:
measure: Survival in both groups
timeFrame: Day 21
Secondary outcomes:
measure: Resolution of SIRS (Systemic Inflammatory Response Syndrome) in both groups
timeFrame: Day 1,2,5,7,14,21
measure: Reduction of ammonia in both groups
timeFrame: Day 1,2,5,7,14,21
measure: Improvement of Cerebral edema in both groups
timeFrame: Day 1,2,5,7,14,21
measure: Improvement in SOFA (Sequential Organ Failure Assessment) Score in both groups
timeFrame: Day 21
Other outcomes:
Locations:
city: New Delhi
country: India
facility: Institute of Liver and Biliary Sciences
state: Delhi
Study officials:
References:
Clinical trial NCT02991222: Bioavailability Study of SPARC001(Study 1) in Healthy Adult Volunteers
Official title: A Randomized, Open-Label, Single-Dose Bioavailability Study of SPARC001 in Healthy, Adult Volunteers Under Fed and Fasted Conditions"
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Sun Pharma Advanced Research Company Limited
Sponsor class: INDUSTRY
First posted: 2016-12-13
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The objective of the study is to determine the relative bioavailability, safety and tolerability of SPARC001 and Reference001 in healthy, adult, male and female subjects


Eligibility criteria: Inclusion Criteria:

1. Adult, male and female volunteers, 18 to 55 years of age, inclusive, at first Check-In Visit;
2. Body mass index (BMI) ≥18 to ≤30 kg/m2 and total body weight \>50 kg (110 lbs) at Screening
3. All female subjects must have a negative serum pregnancy test at Screening and at each Check-in Visit
4. Medically healthy on the basis of medical history

Exclusion Criteria:

1. Females who are pregnant, lactating, or likely to become pregnant during the study
2. Life-time history and/or recent evidence of alcohol or drug/substance abuse disorder
3. Subjects with history or presence of significant cardiovascular, pulmonary, hepatic, gallbladder or biliary tract, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychiatric disease, or active sexually transmitted disease
4. Subjects determined by the investigator to have any medical condition that could jeopardize their health or prejudice the results

Primary outcomes:
measure: AUC
timeFrame: 48 hours
measure: Cmax
timeFrame: 48 hours
Secondary outcomes:
measure: Adverse event
timeFrame: 25 days
Other outcomes:
Locations:
city: Secaucus
country: United States
facility: SPARC Site 01
state: New Jersey
Study officials:
References:
Clinical trial NCT04683822: Telerehabilitation in Patients With Pulmonary Hypertension
Official title: Investigation of the Effectiveness of a Home Exercise Program Combined With Telerehabilitation in Pulmonary Hypertension Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pulmonary Hypertension
Lead sponsor: Marmara University
Sponsor class: OTHER
First posted: 2020-12-24
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Patients with pulmonary hypertension will be randomized into two groups. One group will receive telerehabilitation sessions including upper and lower extremity strengthening exercises and breathing exercises. The other will me monitored routinely. Patients will be assessed by 6 minute walk test, emphasis-10 questionnaire for quality of life and muscle strength with hand-held dynamometer.


Eligibility criteria: Inclusion Criteria:

* Patients with pulmonary hypertension

Exclusion Criteria:

* Patients with severe exercise intolerance
* Patients with musculoskeletal problems that hinder exercise
* Patients who refuse to join the study

Primary outcomes:
measure: Muscle strength
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00826722: Bioequivalency Study of Levetiracetam 1g Under Fasted Conditions
Official title: A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Levetiracetam 1g Tablets Under Fasting Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Seizures
Lead sponsor: West-Ward Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2009-01-22
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The objective of this study was to prove the bioequivalence of Levetiracetam 1000 mg Tablets under fasted conditions


Eligibility criteria: Inclusion Criteria:

* No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening

Exclusion Criteria:

* Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to Levetiracetam or any comparable or similar product.

Primary outcomes:
measure: bioequivalence based on Cmax
timeFrame: 10 days
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: Novum Pharmaceutical Research Services
state: Texas
Study officials:
affiliation: Novum Pharmaceutical Research Services
name: Soran Hong, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03737422: The Effects of Hesperidin and Flaxseed in Prediabetes
Official title: Evaluation of the Effects of Hesperidin and Flaxseed Supplementation in Patients With Prediabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: PreDiabetes
Lead sponsor: National Nutrition and Food Technology Institute
Sponsor class: OTHER
First posted: 2018-11-09
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To study the effects of Hesperidin and flaxseed supplement in patients with prediabetes, 50 patients will be randomly allocated to control group or 2 capsules Hesperidin and 30 gram flaxseed for 12 weeks; both groups will be advised to adherence the investigators' diet and exercise program too. At the first and the end of the intervention, lipid profiles, blood pressure, blood sugar, inflammatory and anthropometric factors will be assessed and compared between groups.


Eligibility criteria: Inclusion Criteria:

* Age of 18 to 70 years prediabetes: impaired fasting glucose (\>100 mg/dL) and/or HbA1C 5.7% to 6.5%, and overweight or obese with body mass index range of 25 to 40 kg/m2

Exclusion Criteria:

* pregnancy or lactation
* A history of Cardiovascular disease, Pulmonary disease, Renal disease \& Celiac disease; Cirrhosis
* Following program to lose weight in recent 3 mo

Primary outcomes:
measure: prediabetes
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: National Nutrition and Food Technology Research Institute
Study officials:
References:
citation: Yari Z, Naser-Nakhaee Z, Karimi-Shahrbabak E, Cheraghpour M, Hedayati M, Mohaghegh SM, Ommi S, Hekmatdoost A. Combination therapy of flaxseed and hesperidin enhances the effectiveness of lifestyle modification in cardiovascular risk control in prediabetes: a randomized controlled trial. Diabetol Metab Syndr. 2021 Jan 6;13(1):3. doi: 10.1186/s13098-020-00619-y.
Clinical trial NCT01640522: Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms
Official title: Phase III Randomized Controlled Trial of a Collaborative Care Intervention to Manage Cancer Related Symptoms in Patients Diagnosed With Hepatobiliary Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hepatocellular Carcinoma
Primary Liver Cancer
Bile Duct Cancer
Pancreatic Cancer
Gallbladder Cancer
Colorectal Carcinoma
Liver Metastases
Keywords: Hepatocellular carcinoma
Cholangio carcinoma
Primary Liver Cancer
Bile Duct CancerPancreatic Cancer
Gallbladder Cancer
Colorectal Carcinoma
Other Primary Cancers with Liver Metastases
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2012-07-13
Enrollment: 261
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Intervention versus standard of care
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to test the efficacy of a collaborative care intervention to manage cancer-related symptoms and improve health related quality of life in patients diagnosed with hepatobiliary carcinoma.

Detailed description: The study is a collaborative care intervention designed to reduce pain, fatigue, and depressive symptoms and improve overall health related quality of life.

Eligibility criteria: Inclusion Criteria:

* biopsy, radiological, and/or biological evidence of hepatobiliary carcinoma
* age 18 years or older
* fluency in English. Exclusion criteria included:

Exclusion Criteria:

* current suicidal or homicidal ideation
* current psychosis or thought disorder

Primary outcomes:
measure: Depression
timeFrame: Change from baseline at 6 and 12 months
Secondary outcomes:
measure: Fatigue
timeFrame: Change from baseline at 6 and 12 months
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: University of Pittsburgh Medical Center
state: Pennsylvania
Study officials:
affiliation: University of Pittsburgh
name: Jennifer L Steel, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00989222: Volar Plating or External Fixation of Dorsally Displaced Fractures of the Distal Radius?
Official title: Volar Plating or External Fixation of Dorsally Displaced Fractures of the Distal Radius? A Prospective Randomized Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Radius Fractures
Keywords: Distal radius fractures
Fractures of the distal radius
Volar plate
External fixation
Lead sponsor: Danderyd Hospital
Sponsor class: OTHER
First posted: 2009-10-05
Enrollment: 63
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Promising results have been reported after volar locked plating of unstable dorsally displaced fractures of the distal radius. It offers stable fixation and early mobilization. The investigators' aim is to test if volar locked plating results in better patient-perceived, objective functional and radiological outcomes compared to the less invasive external fixation that has been the standard operation for decades.


Eligibility criteria: Inclusion Criteria:

* An acute unilateral Colles' fracture (AO class A and C1) with a dorsal angulation of more than 20 degrees or radial shortening of 4 mm or more, AND
* Patient aged 20-70 years with no previous fracture of either wrist.

Exclusion Criteria:

* Bilateral fractures,
* Other current injury to the upper extremities,
* Dementia, OR
* Severe comminution or too small distal fragment to allow plating.

Primary outcomes:
measure: PRWE (patient rated wrist evaluation) score
timeFrame: 3,6 and 12 months
Secondary outcomes:
measure: Objective function (range of movement and grip strength)
timeFrame: 3,6 and 12 months
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Division of Orthopaedics, Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital
Study officials:
affiliation: Karolinska Institutet
name: Gustaf Neander, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06459622: Predictive Factors in Chronic Rhinosinusitis With Nasal Polyps
Official title: Predictive Factors in Chronic Rhinosinusitis With Nasal Polyps
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Chronic Rhinosinusitis With Nasal Polyps
Lead sponsor: Assiut University
Sponsor class: OTHER
Collaborators: name: Assiut University
First posted: 2024-06-14
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: DIAGNOSTIC

Brief summary: The study will be conducted to identify factors predicting the response of chronic rhinosinusitis with nasal polyps ( CRSwNP) to oral corticosteroids.

Detailed description: Treatment of nasal polyposis is divided into medical or surgical treatment .

Steroids are widely used as the most effective medicine in nasal polyposis. Although oral corticosteroids are one of the frequently used treatments in the management of chronic rhinosinusitis with nasal polyps (CRSwNP), there is lack of effective means of predicting corticosteroid sensitivity in those patients. It was reported that the overall sensitivity rates of corticosteroid therapy to nasal polyps( NP) were only between 53.8% and 80%.. Many reports stated that serum and tissue interleukeine 25 (IL 25) and serum and tissue eosinophalia are good predictors to the response of CRSwNP to oral corticosteroids.

Interleukeine 25(IL-25), an important epithelial-derived proinflammatory cytokine, plays various roles in different inflammatory and allergic diseases, such as asthma and atopic dermatitis .

Hong et al demonstrated that the levels of IL-25 in NP tissues and in serum, as well as the NP endoscopic scores, were significantly elevated in the corticosteroid-sensitive patients compared with the non-sensitive ones. In general, eosinophilic NPs are pharmacologically glucocorticoid responsive, but non-eosinophilic or neutrophilic CRSwNP is frequently resistant to steroid treatment.

Eligibility criteria: Inclusion Criteria:

* clinical diagnosis of chronic rhinosinusitis with nasal polyps

Exclusion Criteria:

* 1-Patients who had taken any steroid , antihistamine or other immune-modulating medications within the past 4 weeks

  2- previous nasal and sinus surgery.

  3-Allergic Fungal rhinosinusitis.

  4-Unilateral rhinosinusitis.

  5- Antrochoanal polyps or cystic fibrosis.

Primary outcomes:
measure: Serum IL-25 is measured to releave the relation between them and the response of CRSwNP to oral corticosteroids
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
measure: Eosinophils in nasal polyp tissue
timeFrame: Baseline
Locations:
Study officials:
References:
citation: Shin HW, Kim DK, Park MH, Eun KM, Lee M, So D, Kong IG, Mo JH, Yang MS, Jin HR, Park JW, Kim DW. IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2015 Jun;135(6):1476-85.e7. doi: 10.1016/j.jaci.2015.01.003. Epub 2015 Feb 25.
Clinical trial NCT01463722: Accuracy of Amniotic Fluid Lamellar Body Counting for Evaluating of Fetal Lung Maturity
Official title: Study of Accuracy of Amniotic Fluid Lamellar Body Counting for Evaluating of Fetal Lung Maturity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Retained Fetal Lung Fluid
Keywords: Respiratory distress syndrome
Lung maturity
lamellar body
Lead sponsor: Isfahan University of Medical Sciences
Sponsor class: OTHER
First posted: 2011-11-02
Enrollment: 128
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to determine the accuracy of Amniotic fluid Lamellar Body Counting for Evaluating of Fetal Lung Maturity.

Detailed description: Respiratory distress syndrome (RDS) is one of important cause of mortality in neonates. This study was designed to evaluate the amniotic fluid lamellar body counting for predicting fetal lung maturity.

Eligibility criteria: Inclusion Criteria:

* Women, with 28-37 weeks of gestational age, who had been decided to terminate their pregnancy, were enrolled in the study

Exclusion Criteria:

* Chorioamnionitis
* Intra Uterine Fetal Death (IUFD)
* Blood in amniotic fluid
* Rupture of placenta and patient dissatisfaction were the exclusion criteria.

Primary outcomes:
measure: The statues of respiratory of neonates
timeFrame: at 2 minutes after delivery
Secondary outcomes:
Other outcomes:
Locations:
city: Isfahan
country: Iran, Islamic Republic of
facility: Al-zahra university hospital
Study officials:
affiliation: Isfahan University of Medical Sciences
name: farzaneh memarzadeh, MD
role: STUDY_CHAIR
References:
Clinical trial NCT02291822: Retrospective Study of MRI in Pediatric Patients
Official title: The Safety and Efficacy of MULTIHANCE at the Dose of 0.10 mmol/kg in Magnetic Resonance Imaging of the Central Nervous System in Pediatric Patients Who Are Less Than 2 Years of Age
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Central Nervous System Disease
Central Nervous System Neoplasms
Lead sponsor: Bracco Diagnostics, Inc
Sponsor class: INDUSTRY
First posted: 2014-11-17
Enrollment: 90
Sex: ALL
Maximum age (years): 2
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pediatric patients less than 2 years of age who have previously undergone a MRI of the brain or spine with MultiHance

Brief summary: Collection of already existing data and images for patients \< 2 years of age having MultiHance administration for a MRI of the brain or spine. MR Images will be reviewed during a prospectively designed blinded reading of the images.


Eligibility criteria: Inclusion Criteria:

* Male or female less than 2 years of age at the time of the MRI with MultiHance injection at a dose of 0.1 mmol/kg (± 25% in volume administered)
* Has available demographic and safety data
* Has documented known or highly suspected enhancing disease of the CNS (brain/spine) and previously underwent a cranial or spinal MR examination requiring an injection of MULTIHANCE contrast agent
* Has both pre and post dose T1 SE/FSE and/or GRE and T2 SE/FSE, and FLAIR MR images (when available) for submission to sponsor or designee to be evaluated in a fully blinded read
* Has a documented dose of MultiHance administered for their MRI exam and/or volume (mL) and weight of the patient available to be used to calculate the dose of MultiHance that was administered

Exclusion Criteria:

* Any patient who does not fulfill all of the inclusion criteria

Primary outcomes:
measure: Border delineation of lesions
timeFrame: Immediately post dose - Day 1
measure: Visualization of internal morphology of lesions
timeFrame: Immediately post dose - Day 1
measure: Contrast enhancement of lesions
timeFrame: Immediately post dose- Day 1
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Bracco Diagnostics, Inc
name: Gianpaolo Priovano, M.D.
role: STUDY_DIRECTOR
References: